Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a controlled clinical trial.

Ten patients matched for age, body mass index, functional class, and ejection fraction served as a control group.

Among GH patients, those with an unfavorable outcome had a greater left ventricular end-diastolic diameter (79, 82, and 88 mm) on entry to the study than patients without adverse events (range 62 to 72 mm).

Who Took Part

The study group was 10 patients.

The age groups tagged for this paper are middle-aged adults and older adults, men only.

What Was Measured

Among GH patients, those with an unfavorable outcome had a greater left ventricular end-diastolic diameter (79, 82, and 88 mm) on entry to the study than patients without adverse events (range 62 to 72 mm).

PubMed files the paper under topics including Body Mass Index, Coronary Disease, Drug Evaluation, Echocardiography, Doppler, Exercise Test, Growth Hormone and Heart Failure.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 10 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1999 (The American journal of cardiology), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.